Theme: DeSci Biotech + IP Commercialization

Technical thesis: Biotech projects that combine IP tokenization, milestone-based funding, and reproducibility-aware evaluation agents can route capital toward stronger science and reduce false-positive project selection.

Investor angle: This model can improve portfolio quality for early biotech by tying capital release to verifiable experimental progress rather than narrative-only updates.

Leading indicators:

• Milestone completion per funded project
• Reproducibility score delta after independent validation
• Follow-on funding conversion after first milestone
• Time-to-decision for go/no-go checkpoints

90-day falsifiable predictions:

1. Milestone hit rate improves by >=20% vs non-structured baselines.
2. Capital-at-risk on low-quality projects decreases by >=15%.
3. Follow-on decisions become faster with higher evidence confidence.

Invalidation condition: If reproducibility-linked capital routing does not improve milestone outcomes, the framework needs redesign before scale.